Clinical Trials

Find a Clinical Trial

Enrolling Trials

1-10  of  124
►
10323, Cancer Moonshot Biobank Research Protocol
Onitilo, Adedayo A
Miscellaneous Neoplasm
Adult
To support current and future investigations into drug resistance and sensitivity and other NCI-sponsored cancer research initiatives through the procurement and distribution of multiple longitudinal biospecimens and associated data from a diverse group of cancer patients who are undergoing standard of care treatment
Hurley, Alexa A
(715) 393-1019
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Assess the Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics Profile of BI 764198 Administered Orally Once Daily for 12 Weeks in Patients With Focal Segmental Glomerulosclerosis
Kattamanchi, Siddhartha
Nephrology
Adult
This study is open to adults with a type of kidney disease called primary focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in people with FSGS. Three different doses of BI 764198 are tested in this study. Participants are put into 4 groups randomly, which means by chance. Three of the groups receive different doses of BI 764198 and one group receives placebo. Participants are in the study for about 4 months. For about 3 months, they take BI 764198 or placebo as capsules once a day. Placebo capsules look like BI 764198 capsules but do not contain any medicine. Participants visit the study site about 10 times. You can participate in this study from your home. In this case a research nurse will visit you for the study visits. Kidney health is assessed based on the analysis of urine samples, which participants collect at home. At the end of the study, the results are compared between the different groups. During the study, the doctors also regularly check the general health of the participants.
Kauffman, Lisa D
(715) 389-5738
Mundt, Pamela S
(715) 387-5544
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Upper Limb Essential Tremor
Mosley, Anthony D
Neurology
Adult
Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tasks such as writing, pouring, and eating, and patients also experience associated social embarrassment. This study will assess how safe and effective BOTOX is in treating UL ET. Adverse events and change in disease activity will be evaluated. BOTOX is an investigational drug being developed for the treatment of UL ET. Participants are randomly assigned to 1 of the 4 groups, called treatment arms. Each group receives different treatment. There is 1 in 2 chance that participants will be assigned to placebo. Around 174 participants, aged 18 to 80 years with UL ET will be enrolled in approximately 40 sites in North America. Participants will receive BOTOX or placebo injections in Cycle 1 and Cycle 2. In Cycle 3, participants will receive unilateral or bilateral BOTOX injections. Each cycle is 12 weeks.
Kauffman, Lisa D
(715) 389-5738
Mundt, Pamela S
(715) 387-5544
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study: 5 Independent Sub-studies of Setmelanotide in Patients With POMC, PCSK1, LEPR, SRC1, SH2B1, or PCSK1 N221D Gene Defects in the Melanocortin-4 Receptor Pathway
Meilahn, Jill R
Medical Genetic Study
Adult, Child
The protocol describes a randomized, double-blind, placebo-controlled trial with 5 independent sub-studies of setmelanotide in patients with obesity and at least one of 6 specific gene defects in the Melanocortin-4 Receptor pathway: POMC or PCSK1 (Sub-study 035a); LEPR (Sub-study 035b); SRC1 (Sub-study 035c); SH2B1 (Sub-study 035d); PCSK1 N221D (Sub-study 035e). These 5 sub-studies have high degree of similarities. The objectives and endpoints are identical for all 5 sub-studies.
Freeman, Sandra K
(715) 387-9059
Gault, Tammy
(715) 387-5673
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Onitilo, Adedayo A
Lung - Lung
Adult
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells
Hurley, Alexa A
(715) 393-1019
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop)
Gokalp Yasar, Demet
Melanoma
Adult
This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for patients with unresectable melanoma. This trial is being done to determine if doctors can safely shorten the use of standard of care anti-PD1 therapy for melanoma by using biomarkers seen on PET/CT imaging and tumor biopsy.
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI  54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
Fagbemi, Seth O
Urology - Renal
Adult
This phase III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab in combination with chemotherapy before surgery may enhance the shrinking of the tumor compared to chemotherapy alone.
Wilson, Anna E
(715) 858-6860
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Fagbemi, Seth O
Stomach, Intestine, Gut - Pancreas
Adult
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).
Diagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI  54476
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Eau Claire
2116 Craig Rd
Eau Claire, WI  54701
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
Lee, David
Lung - Lung
Adult
This trial studies the side effects of radiation therapy followed by atezolizumab in treating patients with stage II or III non-small cell lung cancer. Hyperfractionated radiation therapy delivers smaller doses of radiation therapy over time and may kill more tumor cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to test the safety and effectiveness of radiation therapy followed by atezolizumab and find out what side effects, if any, it has on patient's non-small cell lung cancer.
Craig, Chani L
(715) 358-1838
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors
Fagbemi, Seth O
Germ Cell Tumors - Germ Cell
Adult
To estimate the positive predictive value within each of the early stage testicular seminoma and nonseminoma groups using plasma miRNA 371 expression at relapse to detect germ cell malignancy.
Craig, Chani L
(715) 358-1838
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI  54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476